US Cancer Generics Market Outlook 2022 Report Download

“US Cancer Generics Market Outlook 2022” report gives comprehensive insight on the various indicators and trend analysis related to the emergence and integration of cancer generics drugs in mainstream pharmaceutical market in US. The report analyzes various clinical and non-clinical parameters responsible for the growth on cancer generics drugs in recent years. The introduction of generics has resulted in saving of billions of dollars for various stake holders involved US cancer drug market. It is expected that total savings from generics in cancer therapy (in treatment and post treatment) will surpass US$ 30 Billion by 2022 and will further give the required thrust to adoption of generics drugs in cancer therapy as compare to prescribed branded drugs.

“US Cancer Generics Market Outlook 2022” report highlights:

* Introduction to Cancer Generics
* US Generic Drugs Legislature
* US Health Insurance Scenario and Cancer
* Aspects of Branded and Non-Branded Generics
* US Cancer Generics Market Overview

Download Sample

For Report Sample Contact: neeraj@kuickresearch.com

Report Weblink: https://www.kuickresearch.com/report-us-cancer-generics-market-outlook-2022.php

Table of Contents

Cancer Generics: A Modest Regimen
1.1 Introduction to Cancer Generics
1.2 Why There Exist is Need for Generic Forms?
1.3 Supremacy of Cancer Generic Drugs
1.3.1 Cost
1.3.2 Quality and Safety
1.3.3 Large Number of Manufacturer
1.3.4 Approved by FDA
1.3.5 Concerns in Cancer Generic Medication

US Generic Drugs Legislature
2.1 Hatch-Waxman Act, 1984
2.2 The Generic Drugs Chronological Disgrace

Trail towards Patenting of Cancer Generic Drugs
3.1 US Generic Pharmaceutical Regulation
3.2 Patenting Wars of Cancer Generics in US

Economic Burden of Prescription Drugs in US
4.1 High Cost of Cancer Drugs
4.2 Healthcare Savings by Virtue of Generics

Cancer Generic Drugs: Still Overpriced in US Market
5.1 Innovation is Meaningless if Nobody can Afford It
5.2 Why US Contends More in Generics?

US Health Insurance Scenario and Cancer
6.1 Provisions for Cancer Drug Coverage
6.2 Private Health Insurance Options
6.3 Government Funded Insurance

Aspects of Branded and Non-Branded Generics
7.1 Debut of Authorized Generics in Market
7.2 Anti-Authorized Generic Legislation

Generics in Oncology World
8.1 Anti-Cancer Targeted Therapy Drugs
8.2 Status of Generics in Monoclonal Antibodies
8.3 Crusade of Small Molecule Inhibitor towards Generics

FDA Approved Anti-Cancer Generics in US
9.1 Taxotere (Generic Docetaxel)
9.2 Imatinib (Generic Glivec)
9.3 Sorafinib ( Generics Nexavar)

US Cancer Generics Market Overview
10.1 US Cancer Generics Market Introduction
10.2 Europe Generics Market Contrary to US
10.3 Asia Generics Market Contrary to US

Cancer Generics Drug Market Dynamics
11.1 Accelerative Parameters
11.1.1 Expiration of Patents
11.1.2 Unaffordability of Cancer Drugs
11.1.3 Cost Containment by Government
11.1.4 Generic Drug User Fee Amendments (2012)
11.1.5 High Cancer Risk and Aging Population of US
11.2 Pitfalls Confronted by Generic Industry

US Cancer Generics Market Future Prospect

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
L29 - L34, First Floor
Block L,Connaught Place
New Delhi-110001
+91-11-47067990

This release was published on openPR.